Impact of combination rituximab regimens on depth of response and PFS
| . | ORR (%) . | VGPR/CR (%) . | PFS (mo) . |
|---|---|---|---|
| Standard rituximab | 40 | 0-5 | 13 |
| Extended rituximab | 60 | 5-10 | 16-29 |
| Thalidomide rituximab | 70 | 10 | 30% |
| Cyclophosphamide rituximab | 70-80 | 20-25 | 30-36 |
| Nucleoside analogs rituximab | 70-90 | 20-30 | 36-62 |
| Proteasome inhibitors rituximab | 80-90 | 30-40 | 42-66 |
| Bendamustine rituximab | 90 | 30 | 69 |
| . | ORR (%) . | VGPR/CR (%) . | PFS (mo) . |
|---|---|---|---|
| Standard rituximab | 40 | 0-5 | 13 |
| Extended rituximab | 60 | 5-10 | 16-29 |
| Thalidomide rituximab | 70 | 10 | 30% |
| Cyclophosphamide rituximab | 70-80 | 20-25 | 30-36 |
| Nucleoside analogs rituximab | 70-90 | 20-30 | 36-62 |
| Proteasome inhibitors rituximab | 80-90 | 30-40 | 42-66 |
| Bendamustine rituximab | 90 | 30 | 69 |